Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00381719 | Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy | PHASE2 | COMPLETED | 330 | — | — | Oct 1, 2006 | Nov 1, 2007 | Jan 7, 2008 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 3 mg |
| 2 | EXPERIMENTAL | 20 mg |
| 3 | EXPERIMENTAL | 60 mg |
| 4 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AGN 203818 | DRUG | 3 mg Capsule twice daily for 4 weeks |
| placebo capsule | DRUG | Capsule twice daily for 4 weeks |
Inclusion Criteria: * Diagnosis of diabetic peripheral neuropathy * Moderate to severe neuropathic pain Exclusion Criteria: * Any other uncontrolled disease * Pregnant or nursing females